Benitec Biopharma (BNTC) Profit After Tax (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Profit After Tax for 7 consecutive years, with -$16.1 million as the latest value for Q2 2025.
- Quarterly Profit After Tax fell 241.74% to -$16.1 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was -$37.9 million through Jun 2025, down 74.24% year-over-year, with the annual reading at -$37.9 million for FY2025, 74.24% down from the prior year.
- Profit After Tax hit -$16.1 million in Q2 2025 for Benitec Biopharma, down from -$9.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$3.3 million in Q1 2022 to a low of -$16.1 million in Q2 2025.
- Historically, Profit After Tax has averaged -$5.9 million across 5 years, with a median of -$5.1 million in 2021.
- Biggest five-year swings in Profit After Tax: rose 16.22% in 2022 and later crashed 241.74% in 2025.
- Year by year, Profit After Tax stood at -$4.8 million in 2021, then dropped by 12.24% to -$5.4 million in 2022, then fell by 25.63% to -$6.8 million in 2023, then dropped by 8.22% to -$7.4 million in 2024, then plummeted by 119.25% to -$16.1 million in 2025.
- Business Quant data shows Profit After Tax for BNTC at -$16.1 million in Q2 2025, -$9.4 million in Q1 2025, and -$7.4 million in Q4 2024.